Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Editorial, J Virol Antivir Res Vol: 1 Issue: 1
Viral Interferon Antagonism: Making the Leap from the Bench to the Clinic
| Gregory W. Moseley* | |
| Viral Immune Evasion and Pathogenicity Laboratory, Monash University, Australia | |
| Corresponding author : Dr. Gregory W. Moseley Viral Immune Evasion and Pathogenicity Laboratory, Monash University, Australia E-mail: greg.moseley@ monash.edu |
|
| Received: June 20, 2012 Accepted: June 21, 2012 Published: June 23, 2012 | |
| Citation: Moseley GW (2012) Viral Interferon Antagonism: Making the Leap from the Bench to the Clinic. J Virol Antivir Res 1:1. doi:10.4172/2324-8955.1000e103 |
Abstract
Viral Interferon Antagonism: Making the Leap from the Bench to the Clinic
Since the discovery of the type-I interferon (IFN) antiviral cytokines more than 55 years ago, and the subsequent identification of viral products able to inhibit IFN-mediated antiviral responses during the 1960s, it has become increasingly clear that viral interactions with the IFN system form a central host-pathogen interface in determining the outcome of infection. Recent years have seen an explosion in data regarding the mechanisms employed by viruses to subvert the IFNdependent innate immune response, including the identification and detailed molecular characterisation of the mediators of viral immune evasion, collectively termed IFN antagonist proteins.
